NBIX
Price
$168.86Alerts
Change
+$4.23 (+2.57%)
Updated
Nov 9 closing price
Capitalization
16.73B
93 days until earnings call
Intraday BUY SELL Signals
ZYBT
Price
$1.49Alerts
Change
-$0.01 (-0.67%)
Updated
Nov 9 closing price
Capitalization
71.09M
Intraday BUY SELL Signals
Interact to see
Advertisement

NBIX vs ZYBT

NBIX vs ZYBT Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
NBIX vs. ZYBT commentary
Nov 10, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NBIX is a Buy and ZYBT is a Buy.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for NBIX with price predictions
Nov 09, 2026

NBIX in upward trend: 10-day moving average crossed above 50-day moving average on November 03, 2026

The 10-day moving average for NBIX crossed bullishly above the 50-day moving average on November 03, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 15 of 18 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 83%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 22, 2026. You may want to consider a long position or call options on NBIX as a result. In 67 of 87 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 77%.

The Moving Average Convergence Divergence (MACD) for NBIX just turned positive on October 20, 2026. Looking at past instances where NBIX's MACD turned positive, the stock continued to rise in 36 of 53 cases over the following month. The odds of a continued upward trend are 68%.

NBIX moved above its 50-day moving average on November 03, 2026 date and that indicates a change from a downward trend to an upward trend.

Following a +5.70% 3-day Advance, the price is estimated to grow further. Considering data from situations where NBIX advanced for three days, in 224 of 314 cases, the price rose further within the following month. The odds of a continued upward trend are 71%.

Bearish Trend Analysis

The RSI Indicator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 12 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

The 50-day moving average for NBIX moved below the 200-day moving average on October 27, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where NBIX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 55%.

NBIX broke above its upper Bollinger Band on November 03, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for NBIX entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is 43 (best 1 - 100 worst), indicating steady price growth. NBIX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 44 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 45 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock slightly better than average.

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of 61 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.531) is normal, around the industry mean (6.379). P/E Ratio (23.352) is within average values for comparable stocks, (0.548). Projected Growth (PEG Ratio) (0.280) is also within normal values, averaging (2.202). Dividend Yield (0.000) settles around the average of (0.062) among similar stocks. P/S Ratio (4.587) is also within normal values, averaging (183.387).

The Tickeron PE Growth Rating for this company is 82 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

A.I.Advisor
a Summary for ZYBT with price predictions
Nov 09, 2026

ZYBT in upward trend: price rose above 50-day moving average on November 06, 2026

ZYBT moved above its 50-day moving average on November 06, 2026 date and that indicates a change from a downward trend to an upward trend. In 11 of 12 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on November 06, 2026. You may want to consider a long position or call options on ZYBT as a result. In 29 of 35 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 83%.

The Moving Average Convergence Divergence (MACD) for ZYBT just turned positive on November 06, 2026. Looking at past instances where ZYBT's MACD turned positive, the stock continued to rise in 9 of 13 cases over the following month. The odds of a continued upward trend are 69%.

Following a +9.49% 3-day Advance, the price is estimated to grow further. Considering data from situations where ZYBT advanced for three days, in 62 of 77 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.

ZYBT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The 10-day RSI Indicator for ZYBT moved out of overbought territory on October 12, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 10 similar instances where the indicator moved out of overbought territory. In 10 of the 10 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.

The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.

The 10-day moving average for ZYBT crossed bearishly below the 50-day moving average on October 23, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 5 of 6 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 83%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ZYBT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

The Aroon Indicator for ZYBT entered a downward trend on October 08, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is 40 (best 1 - 100 worst), indicating steady price growth. ZYBT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 42 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.656) is normal, around the industry mean (6.379). P/E Ratio (0.000) is within average values for comparable stocks, (0.548). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.202). Dividend Yield (0.000) settles around the average of (0.062) among similar stocks. P/S Ratio (3.795) is also within normal values, averaging (183.387).

The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ZYBT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.

FUNDAMENTALS RATINGS
NBIX: Fundamental Ratings
NBIX
OUTLOOK RATING
1..100
38
VALUATION
overvalued / fair valued / undervalued
1..100
61
Fair valued
PROFIT vs RISK RATING
1..100
45
SMR RATING
1..100
44
PRICE GROWTH RATING
1..100
43
P/E GROWTH RATING
1..100
82
SEASONALITY SCORE
1..100
50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
NBIXZYBT
RSI
ODDS (%)
Bearish Trend 1 day ago
61%
Bearish Trend 1 day ago
90%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
58%
Bearish Trend 1 day ago
90%
Momentum
ODDS (%)
Bullish Trend 1 day ago
77%
Bullish Trend 1 day ago
83%
MACD
ODDS (%)
Bullish Trend 1 day ago
68%
Bullish Trend 1 day ago
69%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
70%
Bullish Trend 1 day ago
83%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
73%
Bullish Trend 1 day ago
82%
Advances
ODDS (%)
Bullish Trend 1 day ago
71%
Bullish Trend 5 days ago
81%
Declines
ODDS (%)
Bearish Trend 9 days ago
55%
Bearish Trend 26 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
68%
Bullish Trend 1 day ago
90%
Aroon
ODDS (%)
Bearish Trend 1 day ago
67%
Bearish Trend 1 day ago
82%
COMPARISON
Comparison
Nov 10, 2026
Stock price -- (NBIX: $168.86 vs. ZYBT: $1.49)
Brand notoriety: NBIX and ZYBT are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: NBIX: 113% vs. ZYBT: 6%
Market capitalization -- NBIX: $16.73B vs. ZYBT: $71.09M
NBIX [@Pharmaceuticals: Generic] is valued at $16.73B. ZYBT’s [@Pharmaceuticals: Generic] market capitalization is $71.09M. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $2.12K to $68.49B. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $4.46B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

NBIX’s FA Score shows that 0 FA rating(s) are green while ZYBT’s FA Score has 0 green FA rating(s).

  • NBIX’s FA Score: 0 green, 5 red.
  • ZYBT’s FA Score: 0 green, 5 red.
According to our system of comparison, NBIX is a better buy in the long-term than ZYBT.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

NBIX’s TA Score shows that 5 TA indicator(s) are bullish while ZYBT’s TA Score has 5 bullish TA indicator(s).

  • NBIX’s TA Score: 5 bullish, 6 bearish.
  • ZYBT’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, ZYBT is a better buy in the short-term than NBIX.

Price Growth

NBIX (@Pharmaceuticals: Generic) experienced а +16.17% price change this week, while ZYBT (@Pharmaceuticals: Generic) price change was +12.03% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +2.25%. For the same industry, the average monthly price growth was -8.53%, and the average quarterly price growth was +7.66%.

Reported Earning Dates

NBIX is expected to report earnings on Feb 11, 2027.

Industries' Descriptions

@Pharmaceuticals: Generic (+2.25% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

View a ticker or compare two or three
Interact to see
Advertisement

ZYBT and

Correlation & Price change

A.I.dvisor tells us that ZYBT and PRGO have been poorly correlated (+28% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ZYBT and PRGO's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ZYBT
1D Price
Change %
ZYBT100%
-0.67%
PRGO - ZYBT
28%
Poorly correlated
+6.94%
AYTU - ZYBT
27%
Poorly correlated
-2.19%
UTHR - ZYBT
23%
Poorly correlated
+3.64%
NBIX - ZYBT
20%
Poorly correlated
+2.57%
ALVO - ZYBT
15%
Poorly correlated
-3.50%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
DZZ1.570.10
+6.80%
Deutsche Bank Ag London Gold Double Short Exchange Traded (Nts) (DZZ)
SEPP32.990.50
+1.53%
PGIM S&P 500 Buffer 12 ETF - September (SEPP)
NFLU11.950.18
+1.53%
T-Rex 2X Long NFLX Daily Target ETF (NFLU)
PJAN50.770.67
+1.34%
Innovator U.S. Equity Power Buffer ETF - January (PJAN)
BSMT22.860.02
+0.11%
Invesco BulletShares 2029 Municipal Bond ETF (BSMT)